MediPharm Labs Corp. (“MediPharm Labs”) today announced it has entered into a share sale and purchase agreement (the “Buyout Agreement”) with its local Australian partner to acquire its 20% ownership interest in the Company’s 80%-owned subsidiary MediPharm Labs Australia. MediPharm is considered a global leader in specialized, research-driven pharmaceutical-quality cannabis extraction and distillation and derivative products. Their new endeavor focuses on developing an Australian facility as part of its strategy to create a global pharmaceutical-quality supply chain that is qualified to serve new emerging medical markets. Upon closing of the Transaction, MediPharm Labs Australia will be a wholly-owned subsidiary of the Company.

Mmp News Author, Medical Marijuana Program Connection, 09/28/2020 07:24:05

Open article: